Antibodiesinc/Pan-Thyroid hormone receptor/73-389/1 Ea
商品编号：
73-389
市场价：
¥0.00
美元价：
0.00
产品分类：
重组抗体
公司分类：
Recombinant_antibodies
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Immunogen:
Fusion protein amino acids 1-410 (full-length) of human Thyroid hormone receptor Alpha1 (also known as Nuclear receptor subfamily 1 group A member 1, V-erbA-related protein 7, c-erbA-1, c-erbA-alpha, THRA, EAR7, ERBA1, NR1A1, THRA1 and Nr1a1, accession number P10827-2)
Mouse: 99% identity (407/410 amino acids identical)
Rat: 99% identity (407/410 amino acids identical)
~90% identity with Thyroid hormone receptor Alpha2
~75% identity with Thyroid hormone receptor Beta1 and Beta2
Fusion protein amino acids 1-410 (full-length) of human Thyroid hormone receptor Alpha1 (also known as Nuclear receptor subfamily 1 group A member 1, V-erbA-related protein 7, c-erbA-1, c-erbA-alpha, THRA, EAR7, ERBA1, NR1A1, THRA1 and Nr1a1, accession number P10827-2)
Mouse: 99% identity (407/410 amino acids identical)
Rat: 99% identity (407/410 amino acids identical)
~90% identity with Thyroid hormone receptor Alpha2
~75% identity with Thyroid hormone receptor Beta1 and Beta2
Specifications:
Target |
|
Pan-Thyroid hormone receptor |
|
|
||
Applications |
|
Immunoblot (IB) Immunocytochemistry (ICC) Immunohistochemistry (IHC) |
|
|
||
Clone |
|
N403/63 |
|
|
||
IgG Isotype |
|
IgG2b |
|
|
||
Species Reactivity |
|
Human (H) Mouse (M) Rat (R) |
|
|
||
Validation |
|
Br-IB Br-IHC T |
|
|
||
Type |
|
TC Supernatant |
|
|
||
Format |
|
5 mL |
|
|
||
Cross Reactivity |
|
Reacts with Thyroid hormone receptor beta1 and beta2 |
|
|
||
Expected Banding Pattern |
|
60 kDa |
|
|
||
Commercial Price |
|
390 |
|
|
||
Non-Profit Price |
|
175 |
|
|
||
Distributor Price |
|
Per Contract(QUOTE) |
|
|
||
ABID |
|
RRID:AB_2336915 |
|
|
||
品牌介绍
当抗体公司（Antibodies Incorporated）在1962年开业时，与抗体相关的研究才刚刚开始。创始人Jim Hillman拥有博士学位。从药理学明尼苏达大学，来到加州大学戴维斯分校在免疫化学完整的博士后工作，在工作期间，他学习了加州理工学院（加州理工学院）根据丹·坎贝尔，领域的先驱。吉姆带来了他的妻子，公司的共同创始人卡罗尔（Carol）和两个孩子，以及使用基于抗体的化学疗法寻找治疗癌症的能量和想法。具体地说，吉姆认为，如果他能够识别并分离出可能具有抗原性的肿瘤部位（一个焦点是淋巴肉瘤），则可能有可能进行有效的基于抗体的治疗。吉姆寻找这种治疗方法的梦想推动了他的工作多年。
